• Schott Pharma posted Q3 2026 revenue of EUR 281.8 million, up 10%, with EBITDA down 8.8% to EUR 75.5 million.
• EBIT fell 15.6% to EUR 53.3 million; profit for the period slipped 14.5% to EUR 39 million; EPS eased to EUR 0.26.
• EBITDA margin narrowed to 26.8% from 32.3%; share of high-value solutions edged down to 59% from 60%.
• Drug Containment Solutions revenue rose 11.3% to EUR 158.9 million; EBITDA dipped 1.1% to EUR 37.9 million.
• Drug Delivery Systems revenue increased 8.6% to EUR 123.2 million; EBITDA dropped 13.4% to EUR 36.3 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schott Pharma AG & Co. KGaA published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.